Dr. Luke Laffin and Dr. C. Michael Gibson discuss: Durability of Effects of CTX310, a CRISPR-Cas9 Gene Editing Targeting ANGPTL3 August 28, 2026 2026 | ESC | Slides | Trial | Video Laffin_Durability CTX310 – ESC – LBCT – 21AUG2026_FINALDownload Disclosures: TBD Article Navigation Dr. Joseph Selvanayagam and Dr. C. Michael Gibson discuss: CMR GUIDE: cardiac magnetic resonance GUIDEd management of mild-moderate left ventricular systolic dysfunction with an ICD Dr. Ashish Sarraju and Dr. C. Michael Gibson discuss: Extremely Long Duration Lp(a) Reduction Following a Single Dose of Kylo-11: Final Data from a First-in-Human Study
